4D Molecular Therapeutics, Inc.
FDMT
$9.48
-$0.39-3.95%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 139.05% | -29.73% | -56.38% | -48.06% | -53.86% |
| Total Depreciation and Amortization | 10.99% | 17.62% | 16.26% | 10.04% | 17.91% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -23.04% | -21.23% | 0.79% | 7.48% | 5.24% |
| Change in Net Operating Assets | 174.10% | -40.93% | 912.35% | -103.72% | -659.94% |
| Cash from Operations | 162.25% | -58.20% | -43.43% | -64.18% | -86.06% |
| Capital Expenditure | 107.38% | 105.12% | 81.09% | 11.13% | -72.86% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1,709.85% | -39.18% | 81.16% | 112.41% | 230.57% |
| Cash from Investing | -1,925.29% | -34.88% | 81.16% | 112.14% | 205.64% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 18,532.61% | -79.58% | -95.00% | -- | -87.38% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 18,532.61% | -79.58% | -95.00% | -- | -87.38% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 130.59% | -1,779.37% | 34.86% | -159.69% | -43.78% |